CannTrust investing approx. CAD $6 million for 20% stake in Australian company Cannatrek. Continue reading CannTrust stakes claim in Australia
Inhaling cannabis makes for easier breathing, because it dilates – or opens up – the airways in the lungs, according to a 1973 study published in New England Journal of Medicine.
Continue reading Breathing easier. Scientists from 1973 already knew that inhaling cannabis could open up airways in the lungs.
GW Pharmaceuticals’ research and development for the therapeutic use of cannabinoids dates back at least two decades.
Continue reading Patents granted to GW Pharmaceuticals for therapeutic use of cannabinoids
Aphria’s Australian-based partner Althea granted Manufacture Licence by the Australian Government’s Office of Drug Control.
Health Canada approval for next phase of vaporized cannabinoid drug clinical trial.
Clinical trial to start and finish by year end Continue reading Health Canada approves next phase of clinical trial to study Tetra Bio-Pharma’s vaporized cannabis drug
Tilray will be part of clinical trial to study possibility that THC and CBD could shrink tumours and increase survival times in brain cancer. Continue reading Tilray and brain-cancer clinical trial in Spain
The University of Colorado School of Medicine is conducting a phase two clinical trial to determine if CBD can reduce symptoms of Parkinson’s disease
Continue reading Phase 2 clinical trial: CBD for Parkinsons
Aurora’s CanniMed cannabis-oil products to be used in a clinical trial for Parkinson’s disease.
The study will determine the safety and tolerability of three different formulations of the cannabis oil for pain in Parkinson’s patients. Continue reading Clinical trial: Aurora cannabis oil for Parkinson’s
A new phase two clinical trial sponsored by University of California Center for Medicinal Cannabis Research is examining the effects of vaporized-cannabis to treat HIV-related neuropathic pain. Continue reading New clinical trial: Vaping for chronic nerve pain in HIV
Tetra’s PPP001 is currently in Phase 3, with the end goal being a DIN,” says Aphria CEO.
“Enormous opportunity” for relationship with Tetra, as supplier and shareholder. Continue reading Aphria CEO shares info on Tetra Bio Pharma during Q1 2019 results